pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,683 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1218Endpoints920BioPharma Dive354BioSpace340Fierce Biotech322onclive165raps111globenewswire health
therapy area
allOncology8299Rare Disease1943Cardiology1880Immunology1591Hematology1354Pulmonology1296Vaccines
  • Thermo Fisher to divest microbiology unit to Astorg for $1.075 billion; Ligand announces purchase of XOMA
    Thermo Fisher Scientific announced it will sell its microbiology business, part of its specialty diagnostics segment, to European private‑equity firm Astorg. The transaction is valued at $1.075 bi…
    Endpoints · 4mo agoDealNeutral↗ source
  • Oruka Therapeutics reports Phase 2 psoriasis results with 63% of patients showing plaque improvement
    Oruka Therapeutics announced results from its Phase 2 trial in moderate to severe plaque psoriasis. The study enrolled 63 patients and 40 of them, about 63.5%, achieved the predefined level of ski…
    Endpoints · 4mo agoPositive readoutPositive↗ source
← prev
page 67 of 68
next →
73
fda recalls71
fda medwatch63
fda press38
1279
Psychiatry & CNS899
Ophthalmology521
Pain503
Endocrinology & Metabolism497
Infectious Disease459
  • AI-driven biotech Fathom Therapeutics secures $47 million Series A funding and rebrands from Atommap
    Fathom Therapeutics, the company formerly known as Atommap, announced that it has closed a $47 million Series A financing round. The capital raise will support the firm’s effort to combine artifici…
    Endpoints · 4mo agoDealPositive↗ source
  • Veradermics reports positive Phase 2/3 results for oral Rogaine in men with pattern hair loss
    Veradermics, a biotech that recently went public, announced that its oral formulation of Rogaine met the primary endpoints in a late-stage Phase 2/3 trial. The study enrolled men with mild-to-mode…
    Endpoints · 4mo agoPositive readoutPositive↗ source
  • Revolution Medicines threatens lawsuit against Erasca over RAS drug patent and efficacy claims
    Earlier this month a newly announced cancer therapy generated strong interest from patients and investors. The drug, which targets the RAS pathway, was highlighted for its potential impact on oncol…
    Endpoints · 4mo agoRegulatoryNegative↗ source
  • Utah doctors urge state to suspend Doctronic AI prescription-refill program
    Utah medical licensing board members have asked the state to halt a temporary program that lets startup Doctronic use artificial intelligence to refill prescriptions. The board says the AI-driven…
    Endpoints · 4mo agoRegulatoryNegative↗ source
  • UK biotech funding shows early recovery after mid-2025 lull, BIA reports
    The BioIndustry Association released data indicating that equity financing for UK biotech companies is beginning to rise again in early 2026. The trend follows a slowdown that began in mid-2025, w…
    Endpoints · 4mo agoPositive↗ source
  • Endpoints Weekly celebrates Neal Awards while previewing Sanofi, Lilly and RevMed updates
    Endpoints Weekly released its latest edition on April 25, 2026, noting a celebratory tone after the publication earned three Neal Awards for B2B journalism excellence. The issue highlights several…
    Endpoints · 4mo agoPositive↗ source
  • Sanofi’s tolebrutinib receives EU CHMP endorsement for specific multiple sclerosis patients despite US FDA setback
    Sanofi's BTK inhibitor tolebrutinib is moving toward approval in the European Union for a subset of multiple sclerosis patients. The Committee for Medicinal Products for Human Use (CHMP) of the Eu…
    Endpoints · 4mo agoRegulatoryPositive↗ source
  • Avalyn Pharma targets $182M IPO as WHO prequalifies Novartis malaria drug
    Avalyn Pharma announced plans for an initial public offering that could raise about $182 million in net proceeds. The company is developing inhaled formulations of drugs already approved for pulmon…
    Endpoints · 4mo agoDealNeutral↗ source
  • Novartis withdraws EU filing for Pluvicto label expansion into early-stage prostate cancer
    Novartis announced it has pulled its application to the European Medicines Agency to extend the label of its radioligand therapy Pluvicto for use in earlier stages of prostate cancer. The move com…
    Endpoints · 4mo agoRegulatoryNegative↗ source
  • FDA grants fast-track vouchers to three psychedelic firms
    The FDA announced it has issued fast-track development vouchers to three companies working on psychedelic therapies. The recipients are R&DCompass, Transcend, and the Usona Institute. The vouchers…
    Endpoints · 4mo agoRegulatoryPositive↗ source
  • UC Berkeley spinout explores gene-editing approach to GLP-1 based weight-loss therapy
    UC Berkeley researchers have launched a startup that plans to use jumping genes to deliver GLP-1 gene therapy for obesity treatment. The approach seeks to create a long-lasting source of the hormon…
    Endpoints · 4mo agoNeutral↗ source
  • Daiichi Sankyo delays release of annual results, shares fall
    Daiichi Sankyo announced it will postpone the reporting of its annual results, saying more time is needed to finalize the numbers. The company had planned to unveil the financials for its fiscal y…
    Endpoints · 4mo agoNegative↗ source
  • Pfizer strategy chief Andrew Baum departs, stays on as senior advisor; Helus Pharma appoints new CEO after two months
    Andrew Baum, formerly chief strategy and innovation officer at Pfizer, has left that role. He will continue to work with the company as a senior strategic advisor to CEO Albert Bourla. Meanwhile,…
    Endpoints · 4mo agoNeutral↗ source
  • Regeneron secures first FDA approval for gene therapy treating rare inherited hearing loss
    Regeneron announced that the U.S. Food and Drug Administration has approved its gene-based treatment Otarmeni, marking the first approval of a therapy for inherited hearing loss. The therapy is de…
    Endpoints · 4mo agoApprovalPositive↗ source
  • Novo Nordisk's GLP-1 pill shows blood-sugar reduction in teens with type 2 diabetes
    Novo Nordisk reported results from a study evaluating its oral GLP-1 therapy, Rybelsus, in adolescents with type 2 diabetes. The trial enrolled participants aged 10-17 who took the pill for roughl…
    Endpoints · 4mo agoPositive readoutPositive↗ source
  • Roche remains bullish on giredestrant despite first-line trial setback
    Roche's CEO Thomas Schinecker said the company still expects its investigational oral breast cancer therapy giredestrant to generate strong sales, potentially surpassing Herceptin. The optimism fo…
    Endpoints · 4mo agoNegative readoutNeutral↗ source
  • Novartis' Lutathera radioligand therapy may soon face first generic challenger
    Novartis has built a sizable business delivering radioligand therapies, with Lutathera being a leading product. A rival company is preparing to launch the first generic version, which could introd…
    Endpoints · 4mo agoNegative↗ source
  • Amneal to acquire biosimilar maker for $375 million upfront
    Amneal Pharmaceuticals announced it will purchase a biosimilar development company, agreeing to pay $375 million in an upfront cash payment. The deal expands Amneal’s portfolio in the growing biosi…
    Endpoints · 4mo agoDealNeutral↗ source
  • Sanofi defends Garijo appointment and reaffirms commitment to immunology ahead of new CEO
    Sanofi held its first-quarter earnings call, with CFO François-Xavier Roger fielding questions from the media. During the call he defended the recent appointment of Belén Garijo, formerly of Merck…
    Endpoints · 4mo agoEarningsNeutral↗ source
  • Substance-use disorder biotech Tempero Bio shuts down after serious safety incident
    Tempero Bio, a biotech focused on treatments for substance use disorders, announced it will cease operations. The decision follows a serious adverse event that occurred during the company's develo…
    Endpoints · 4mo agoNegative↗ source
  • Endpoints News earns three Neal Awards for Trump coverage, CRISPR series and JPM event
    Endpoints News was honored with three Neal Awards in 2026. The awards recognize its reporting on the pharmaceutical industry's interactions with the Trump administration, a three-part series explo…
    Endpoints · 4mo agoPositive↗ source
  • Gravity Rail secures $2.75 million seed round to expand AI-driven patient communication platform
    Gravity Rail is a new company that builds artificial intelligence tools to help health care providers manage phone calls, text messages and follow‑up tasks with patients. The platform aims to strea…
    Endpoints · 4mo agoDealPositive↗ source
  • Trump nominates former deputy surgeon general Erica Schwartz as CDC director, testing MAHA influence
    President Trump has announced Erica Schwartz, a former deputy surgeon general, as the new CDC director. Schwartz is known for supporting vaccination and is seen as a traditional public‑health choic…
    Endpoints · 4mo agoRegulatoryNeutral↗ source